SBP Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium

  • SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel
  • Objective Response Rate (ORR) was 62% by RECIST criteria
  • Study expansion in patients with pancreatic cancer planned to begin in Q2

View/download press release »
View/download poster presentation »